ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc.

ALX Oncology Holdings ( ($ALXO) ) has shared an announcement. ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026, ...

Market Cap	$185.70M	P/E Ratio	N/A
52W High	$2.66	52W Low	$0.40
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.4%	52W Position	49.9%
Overall Score	41	Value Score	60
Quality Score	18	Technical Score	45

EPS Current Est	$-0.66	EPS Next Est	$-0.63
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALXO	$1.53	+5.52%	5.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALXO	$1.53	+5.5%	5.05M
3
4
5
6

ALXO

ALXO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ALX Oncology Holdings Inc. Data in Excel

Get ALX Oncology Holdings Inc. Data in Excel